{"filepath": "../L2M3_data/0_csd_related_papers/ACS_XML/cg5b01274.xml", "publisher": "acs", "elements": [{"idx": 1, "type": "text", "classification": ["else"], "content": "<p>We\nhave synthesized a novel zinc metal\u2013organic framework (MOF)\nunder mild hydrothermal routes using 5-aminotetrazole and methyl-2-amino-4-isonicotinate\nanionic ligands. The MOF exhibits a three-dimensional structure with\nintense blue-greenish photoluminescence emission at room temperature\nin the solid state. The luminescence, porosity, and adsorption capacity\nfor CO<sub>2</sub> and H<sub>2</sub> of the Zn-based MOF have been\nfully determined using a combination of computational methods and\nexperimental techniques. The synthesized Zn-based compound in this\nstudy exhibited a remarkable in vivo anti-diabetic activity and low\nin vitro cell toxicity.</p>", "clean_text": "We have synthesized a novel zinc metal-organic framework (MOF) under mild hydrothermal routes using 5-aminotetrazole and methyl-2-amino-4-isonicotinate anionic ligands. The MOF exhibits a three-dimensional structure with intense blue-greenish photoluminescence emission at room temperature in the solid state. The luminescence, porosity, and adsorption capacity for CO2 and H2 of the Zn-based MOF have been fully determined using a combination of computational methods and experimental techniques. The synthesized Zn-based compound in this study exhibited a remarkable in vivo anti-diabetic activity and low in vitro cell toxicity.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 2, "type": "text", "classification": ["else"], "content": "<p>We have designed\nand synthesized a novel zinc metal\u2212organic-framework (MOF)\nunder mild hydrothermal routes using 5-aminotetrazole and methyl-2-amino-4-isonicotinate\nanionic ligands. The MOF exhibits a three-dimensional structure with\nintense blue-greenish photoluminescence emission at room temperature\nin the solid state. The Zn-based compound designed in this study exhibited\na remarkable in vivo anti-diabetic activity and low in vitro cell\ntoxicity.</p>", "clean_text": "We have designed and synthesized a novel zinc metal-organic-framework (MOF) under mild hydrothermal routes using 5-aminotetrazole and methyl-2-amino-4-isonicotinate anionic ligands. The MOF exhibits a three-dimensional structure with intense blue-greenish photoluminescence emission at room temperature in the solid state. The Zn-based compound designed in this study exhibited a remarkable in vivo anti-diabetic activity and low in vitro cell toxicity.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 3, "type": "text", "classification": ["else"], "content": "<p>In the last\ntwo decades, metal\u2013organic frameworks (MOFs) have attracted\nmuch attention due to their exceptional properties. MOFs\nare built up from metal ions or clusters connected through organic\nlinkers giving rise to a large diversity of multidimensional structures.\nThe large variety of organic molecules that may act as linkers make\npossible the rational design of novel MOF structures, tailoring both\nthe chemical and physical properties of the framework. Nowadays, MOFs\nhave evolved enormously in areas such as luminescence, gas adsorption, drug delivery, sensing and optical storage. In the last few years,\nwe have designed and synthesized novel Zn-based MOFs with different\nnitrogen derivative ligands with interesting luminescent properties,\nsuch as tetrazolate and pyrimidine linkers. Methyl-2-amino-4-isonicotinic acid was selected in this work as\na potential linker due to its different coordination modes to form\nnew MOF structures. To the best of our knowledge, five compounds comprising\nonly two isostructural MOF materials based on different metals ions\nsuch as cadmium, cobalt, and zinc have been described in the literature\nusing this ligand. Following these works, we report\nhere the synthesis, structure, luminescence, stability, and adsorption\nof a novel zinc MOF based on 5-aminotetrazole (Hatz) and 2-amino-4-isonicotinic\n(Hain) ligands [Zn\u00ad(ain)\u00ad(atz)]<sub>\n<italic>n</italic>\n</sub> (<bold>1</bold>). We demonstrate the potential of the ain<sup>\u20131</sup> anionic linker and the secondary nitrogen ligand atz<sup>\u20131</sup> to construct novel MOFs. Thanks to its extended aromaticity and\nto the presence of poly-heterosubstituted penta- and hexa-atomic rings,\nthese linkers are good candidates to show enhanced emissive properties,\nwhich may be tunable by coordination to different metals with different\nchemical environments.</p>", "clean_text": "In the last two decades, metal-organic frameworks (MOFs) have attracted much attention due to their exceptional properties. MOFs are built up from metal ions or clusters connected through organic linkers giving rise to a large diversity of multidimensional structures. The large variety of organic molecules that may act as linkers make possible the rational design of novel MOF structures, tailoring both the chemical and physical properties of the framework. Nowadays, MOFs have evolved enormously in areas such as luminescence, gas adsorption, drug delivery, sensing and optical storage. In the last few years, we have designed and synthesized novel Zn-based MOFs with different nitrogen derivative ligands with interesting luminescent properties, such as tetrazolate and pyrimidine linkers. Methyl-2-amino-4-isonicotinic acid was selected in this work as a potential linker due to its different coordination modes to form new MOF structures. To the best of our knowledge, five compounds comprising only two isostructural MOF materials based on different metals ions such as cadmium, cobalt, and zinc have been described in the literature using this ligand. Following these works, we report here the synthesis, structure, luminescence, stability, and adsorption of a novel zinc MOF based on 5-aminotetrazole (Hatz) and 2-amino-4-isonicotinic (Hain) ligands [Zn(ain)(atz)] n  (1). We demonstrate the potential of the ain-1 anionic linker and the secondary nitrogen ligand atz-1 to construct novel MOFs. Thanks to its extended aromaticity and to the presence of poly-heterosubstituted penta- and hexa-atomic rings, these linkers are good candidates to show enhanced emissive properties, which may be tunable by coordination to different metals with different chemical environments.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 4, "type": "text", "classification": ["else"], "content": "<p>The synthesized compound <bold>1</bold> has a potential interest in the treatment of diabetes, a pathology\nwhere Zn-containing compounds have shown promising hypoglycemic properties. Hyperglycemia is a common effect of uncontrolled diabetes and over\ntime leads to serious damage of the body system. Zinc has shown insulin-like effects by supporting the signal\ntransduction of insulin and by reducing the production of cytokines,\nwhich lead to beta-cell death during the inflammatory process in the\npancreas in the course of the disease. Genetic polymorphisms in the\ngene of zinc transporter and in metallothionein (MT)-encoding genes\ncould be related to type 2 diabetes mellitus. Antibodies against this\nzinc transporter have been detected in type 1 diabetic patients. It has been demonstrated that Zn compounds inhibit\nthe protein-tyrosine phosphatase 1B (PTP1B) enzyme that plays a major\nrole in modulating both insulin sensitivity and fuel metabolism. The synthesis of this new three-dimensional\n(3D) Zn carrier structure <bold>1</bold> could be an excellent tool\nto improve the distribution of Zn and therefore its effectiveness\nas oral anti-diabetic agent in the treatment of diabetes mellitus,\nbecoming an alternative or synergistic agent to traditional parenteral\ninsulin therapy. The treatment of diabetic rats with this Zn-based\nMOF synthesized in this study is pioneering and opens a new line of\nresearch in the field of healthcare applications of MOFs and the pharmacological\ntreatment of diabetes.</p>", "clean_text": "The synthesized compound 1 has a potential interest in the treatment of diabetes, a pathology where Zn-containing compounds have shown promising hypoglycemic properties. Hyperglycemia is a common effect of uncontrolled diabetes and over time leads to serious damage of the body system. Zinc has shown insulin-like effects by supporting the signal transduction of insulin and by reducing the production of cytokines, which lead to beta-cell death during the inflammatory process in the pancreas in the course of the disease. Genetic polymorphisms in the gene of zinc transporter and in metallothionein (MT)-encoding genes could be related to type 2 diabetes mellitus. Antibodies against this zinc transporter have been detected in type 1 diabetic patients. It has been demonstrated that Zn compounds inhibit the protein-tyrosine phosphatase 1B (PTP1B) enzyme that plays a major role in modulating both insulin sensitivity and fuel metabolism. The synthesis of this new three-dimensional (3D) Zn carrier structure 1 could be an excellent tool to improve the distribution of Zn and therefore its effectiveness as oral anti-diabetic agent in the treatment of diabetes mellitus, becoming an alternative or synergistic agent to traditional parenteral insulin therapy. The treatment of diabetic rats with this Zn-based MOF synthesized in this study is pioneering and opens a new line of research in the field of healthcare applications of MOFs and the pharmacological treatment of diabetes.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 5, "type": "text", "classification": ["synthesis condition"], "content": "<p>Soft hydrothermal reaction of zinc acetate\n(0.2 mmol) with 5-aminotetrazole (0.2 mmol) and methyl-2-amino-4-isonicotinic\nacid (0.2 mmol) in water/methanol (10 mL) at 150 \u00b0C for 12 h\nfollowed by cooling to room temperature over 3 h produced prismatic\ncolorless crystals of <bold>1</bold> in 65% yield (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Supporting Information</ext-link>). The crystal structure was determined\nusing single crystal X-ray diffraction. The asymmetric unit consists on one zinc atom, one ain<sup>\u20131</sup> ligand, and one atz<sup>\u20131</sup> linker. Zn ion exhibits\ndistorted tetrahedral ZnN<sub>3</sub>O geometry () with N1B and N4B nitrogen\natoms belonging to tetrazolate group, one oxygen atom pertaining to\na carboxylate group, and a N1A atom from pyridine ring of the anionic\nain<sup>\u20131</sup> ligand.</p>", "clean_text": "Soft hydrothermal reaction of zinc acetate (0.2 mmol) with 5-aminotetrazole (0.2 mmol) and methyl-2-amino-4-isonicotinic acid (0.2 mmol) in water/methanol (10 mL) at 150 \u00b0C for 12 h followed by cooling to room temperature over 3 h produced prismatic colorless crystals of 1 in 65% yield (Supporting Information). The crystal structure was determined using single crystal X-ray diffraction. The asymmetric unit consists on one zinc atom, one ain-1 ligand, and one atz-1 linker. Zn ion exhibits distorted tetrahedral ZnN3O geometry () with N1B and N4B nitrogen atoms belonging to tetrazolate group, one oxygen atom pertaining to a carboxylate group, and a N1A atom from pyridine ring of the anionic ain-1 ligand.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['synthesis condition']"}}, {"idx": 6, "type": "figure", "classification": null, "content": "<fig id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>A view of the metal environment and coordination\nmodes of the ligands for 1. Color code: N = blue, O = red, C = gray,\nZn = yellow.</p>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"cg-2015-012748_0002.tif\"></graphic>\n</fig>", "clean_text": " 1  A view of the metal environment and coordination modes of the ligands for 1. Color code: N = blue, O = red, C = gray, Zn = yellow.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 7, "type": "text", "classification": "error", "content": "<p>Each ain<sup>\u20131</sup> and atz<sup>\u20131</sup> connects two zinc ions through O2A and\nN1A (for ain<sup>\u20131</sup>), resulting in the formation of a\n3D MOF (),\nin which each tetrazolate moiety also coordinates in a bidentate fashion\n(N1B\u2013N4B) to zinc atoms. Zn\u2013N distances are in the range\nof 2.002(4)\u20132.019(3) \u00c5, whereas the Zn\u2013O distance\nhas a value of 1.929(3) \u00c5, for O2A. Cis bond angles of metal\nenvironment are in the range of 93.01(14)\u2013118.11(14)\u00b0,\nand ZnII\u00b7\u00b7\u00b7ZnII distances through ain<sup>\u20131</sup> and atz<sup>\u20131</sup> bridge ligands are 8.892 and 5.980 \u00c5,\nrespectively. The crystalline structure of this 3D MOF generates two\ntypes of channels along the <italic>b</italic> axis with different\ngroups oriented toward the center of the pores (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S1</ext-link>). In the A pore, there are carboxylate and amino\ngroups from ain<sup>\u20131</sup> and atz<sup>\u20131</sup>, respectively,\nwhile in B pore there are amino and tetrazolate groups pertaining\nto ain<sup>\u20131</sup> and atz<sup>\u20131</sup>, respectively.\nBecause of the existence of these pores in the structure, the porosity\nand adsorption capacity for CO<sub>2</sub> and H<sub>2</sub> of the\nZn-based MOF have been fully determined without finding significant\nresults (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Supporting Information</ext-link>).</p>", "clean_text": "Each ain-1 and atz-1 connects two zinc ions through O2A and N1A (for ain-1), resulting in the formation of a 3D MOF (), in which each tetrazolate moiety also coordinates in a bidentate fashion (N1B-N4B) to zinc atoms. Zn-N distances are in the range of 2.002(4)-2.019(3) \u00c5, whereas the Zn-O distance has a value of 1.929(3) \u00c5, for O2A. Cis bond angles of metal environment are in the range of 93.01(14)-118.11(14)\u00b0, and ZnII\u22c5\u22c5\u22c5ZnII distances through ain-1 and atz-1 bridge ligands are 8.892 and 5.980 \u00c5, respectively. The crystalline structure of this 3D MOF generates two types of channels along the b axis with different groups oriented toward the center of the pores (Figure S1). In the A pore, there are carboxylate and amino groups from ain-1 and atz-1, respectively, while in B pore there are amino and tetrazolate groups pertaining to ain-1 and atz-1, respectively. Because of the existence of these pores in the structure, the porosity and adsorption capacity for CO2 and H2 of the Zn-based MOF have been fully determined without finding significant results (Supporting Information).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 8, "type": "figure", "classification": null, "content": "<fig id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>View down the <italic>b</italic> axis of the structure in the three-dimensional network.\nHydrogen atoms have been omitted for clarity. Color code: N = blue,\nO = red, C = gray, Zn = yellow.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"cg-2015-012748_0003.tif\"></graphic>\n</fig>", "clean_text": " 2  View down the b axis of the structure in the three-dimensional network. Hydrogen atoms have been omitted for clarity. Color code: N = blue, O = red, C = gray, Zn = yellow.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 9, "type": "text", "classification": "error", "content": "<p>The extended aromaticity of the anionic ligands and the use\nof d<sup>10</sup> metal ions in <bold>1</bold> suggest the existence\nof enhanced emissive properties in this MOF. <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S7</ext-link> shows the emission spectrum of compound <bold>1</bold> in\nthe solid state at room temperature upon excitation at 322 nm. This\ncompound exhibits a broad intense emission band centered at 420 nm.\nThe emission in compound <bold>1</bold> can be tentatively assigned\nto the metal to ligand charge transfer (MLCT) and/or to the ligand\nto ligand charge transfer (LLCT). The emission of <bold>1</bold> is\nsignificantly red-shifted compared to that of the isolated ligand.\nThis bathochromism may be due to Zn ions showing higher d* energy\nlevels, which is consistent with similar bathochromic shifts that\nhave been observed in other compounds.\n</p>", "clean_text": "The extended aromaticity of the anionic ligands and the use of d10 metal ions in 1 suggest the existence of enhanced emissive properties in this MOF. Figure S7 shows the emission spectrum of compound 1 in the solid state at room temperature upon excitation at 322 nm. This compound exhibits a broad intense emission band centered at 420 nm. The emission in compound 1 can be tentatively assigned to the metal to ligand charge transfer (MLCT) and/or to the ligand to ligand charge transfer (LLCT). The emission of 1 is significantly red-shifted compared to that of the isolated ligand. This bathochromism may be due to Zn ions showing higher d* energy levels, which is consistent with similar bathochromic shifts that have been observed in other compounds. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 10, "type": "text", "classification": "error", "content": "<p>In order\nto understand the origin of the observed emission, time-dependent\ndensity functional theory (TD-DFT) theoretical calculations were performed.\nStudies revealed that the band observed in the emission spectrum of\ncompound <bold>1</bold> arises from the interligand charge transfer between the two pairs of \u03c0 stacked 2-amino-isonicotinic ligands.\nIn this respect, model 1 shows a smoothed emission band with a maximum\nat 466 nm ( and ), as a consequence\nof LUMO \u2192 HOMO (376 nm), LUMO+1 \u2192 HOMO\u20131 (489\nnm), and LUMO+1 \u2192 HOMO\u20132 (513 nm) electron relaxation\nprocesses (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S9</ext-link>). The mentioned molecular\norbitals are delocalized over the entire 2-amino-isonicotinic moieties\n( and ).</p>", "clean_text": "In order to understand the origin of the observed emission, time-dependent density functional theory (TD-DFT) theoretical calculations were performed. Studies revealed that the band observed in the emission spectrum of compound 1 arises from the interligand charge transfer between the two pairs of \u03c0 stacked 2-amino-isonicotinic ligands. In this respect, model 1 shows a smoothed emission band with a maximum at 466 nm ( and ), as a consequence of LUMO \u2192 HOMO (376 nm), LUMO+1 \u2192 HOMO-1 (489 nm), and LUMO+1 \u2192 HOMO-2 (513 nm) electron relaxation processes (Figure S9). The mentioned molecular orbitals are delocalized over the entire 2-amino-isonicotinic moieties ( and ).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 11, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Calculated Emission Bands and Involved Electronic Transitions in\nModel 1</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"3\">\n<oasis:colspec align=\"char\" char=\".\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">max\u00a0\u03bb (nm) emission</oasis:entry>\n<oasis:entry align=\"center\">calc transitions</oasis:entry>\n<oasis:entry align=\"center\">osc strength</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>376</oasis:entry>\n<oasis:entry>L\u00a0\u2192\u00a0H (88%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>489</oasis:entry>\n<oasis:entry>L+1\u00a0\u2192 H-2 (95%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>513</oasis:entry>\n<oasis:entry>L+1\u00a0\u2192 H-1 (96%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Calculated normalized\nemission spectrum of model 1, upon application of a Gaussian filter\nto theoretical data (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S8</ext-link>). The three\nmaxima observed in the original spectrum are indicated as red circles.</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"cg-2015-012748_0004.tif\"></graphic>\n</fig>", "clean_text": " 3  Calculated normalized emission spectrum of model 1, upon application of a Gaussian filter to theoretical data (Figure S8). The three maxima observed in the original spectrum are indicated as red circles.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 13, "type": "text", "classification": "error", "content": "<p>With the aim of using this MOF\nin healthcare applications, we determined the effect of compound <bold>1</bold> on HEK293 cell viability by using MTS assays\n(<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figures S10 and S11</ext-link>). We found that in\nthe presence of the highest concentration of tested compound <bold>1</bold> (100 \u03bcM), cell proliferation of HEK293 was decreased\nto 80\u201375%, and 70% in 48 and 72 h, respectively, compared with\nthe control cells (<italic>p</italic> &lt; 0.05). In 24 h, we did\nnot find any significant variation in the cell viability measurements.\nImportantly, we demonstrated that compound <bold>1</bold> had a significantly\nlow cytotoxicity, thereby providing a rationale clinical use of compound <bold>1</bold> as a promising anti-diabetic agent.</p>", "clean_text": "With the aim of using this MOF in healthcare applications, we determined the effect of compound 1 on HEK293 cell viability by using MTS assays (Figures S10 and S11). We found that in the presence of the highest concentration of tested compound 1 (100 \u03bcM), cell proliferation of HEK293 was decreased to 80-75%, and 70% in 48 and 72 h, respectively, compared with the control cells (p < 0.05). In 24 h, we did not find any significant variation in the cell viability measurements. Importantly, we demonstrated that compound 1 had a significantly low cytotoxicity, thereby providing a rationale clinical use of compound 1 as a promising anti-diabetic agent.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 14, "type": "text", "classification": "error", "content": "<p>In vivo experiments\nwere carried out using male Wistar rats. Results showed that compound <bold>1</bold> had no effect on body weight after the experimental period\n(10 days). However, it showed a significant reduction of food and\nwater intake, thus alleviating the hyperphagia and polydipsia that\naccompanies diabetes. Fasting glycemia levels also significantly decreased\nin the group of rats treated with the compound <bold>1</bold> in comparison\nwith the untreated diabetic group of rats ().</p>", "clean_text": "In vivo experiments were carried out using male Wistar rats. Results showed that compound 1 had no effect on body weight after the experimental period (10 days). However, it showed a significant reduction of food and water intake, thus alleviating the hyperphagia and polydipsia that accompanies diabetes. Fasting glycemia levels also significantly decreased in the group of rats treated with the compound 1 in comparison with the untreated diabetic group of rats ().", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 15, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl2\" position=\"float\">\n<label>2</label>\n<caption>\n<title>Data Are Presented\nAs Mean \u00b1 SD<xref rid=\"tbl2-fn1\"></xref>\n</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"5\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\"\u00b1\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\"\u00b1\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"center\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"center\" colname=\"col5\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">body weight (g)</oasis:entry>\n<oasis:entry align=\"center\">food intake (g)</oasis:entry>\n<oasis:entry align=\"center\">water\nintake (mL)</oasis:entry>\n<oasis:entry align=\"center\">fasting glycemia (mg/dL)</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>control</oasis:entry>\n<oasis:entry>256\u00a0\u00b1\u00a07</oasis:entry>\n<oasis:entry>16.5\u00a0\u00b1\u00a00.7</oasis:entry>\n<oasis:entry>15.3\u00a0\u00b1\u00a06.1</oasis:entry>\n<oasis:entry>81.3\u00a0\u00b1\u00a05.4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>diabetic</oasis:entry>\n<oasis:entry>223\u00a0\u00b1\u00a017<sup>a</sup>\n</oasis:entry>\n<oasis:entry>42.3\u00a0\u00b1\u00a00.9<sup>a</sup>\n</oasis:entry>\n<oasis:entry>310.2\u00a0\u00b1\u00a028.7<sup>a</sup>\n</oasis:entry>\n<oasis:entry>272.8\u00a0\u00b1\u00a018<sup>a</sup>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>diabetic treated</oasis:entry>\n<oasis:entry>217\u00a0\u00b1\u00a012<sup>b</sup>\n</oasis:entry>\n<oasis:entry>35.7\u00a0\u00b1\u00a00.5<sup>b,c</sup>\n</oasis:entry>\n<oasis:entry>190.1\u00a0\u00b1\u00a042.8<sup>b,c</sup>\n</oasis:entry>\n<oasis:entry>237.3\u00a0\u00b1\u00a022<sup>b,c</sup>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"tbl2-fn1\">\n<label>a</label>\n<p>a, control vs diabetic, b, control vs diabetic treated, and c, diabetic\nvs diabetic treated. <italic>p</italic> &lt; 0.05.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 16, "type": "text", "classification": "error", "content": "<p>The main result obtained in these\nin vivo experiments is the notable improvement in the oral glucose\ntolerance test (OGTT) test (). The group of rats treated with the Zn-containing\ncompound developed in this study showed an important decrease of the\nblood glucose levels 30 min after the oral glucose load in comparison\nwith the untreated diabetic group of rats, which suffered a sustained\nincrease 120 min later. In the Zn treated diabetic group of rats,\nthe glycemia decreased \u223c18% and \u223c40%, 30 and 120 min\nafter the oral glucose load, respectively, in comparison with the\nuntreated diabetic rats. Despite the advanced stage of the diabetes,\nas evidenced by the presence of fasting blood glucose levels higher\nthan 250 mg/dL in the two groups of diabetic rats, compound <bold>1</bold> showed advantages over other conventional compounds tested\nin other studies at the same dose. The\nZn compound tested by Ohly et al. did not achieve a decrease of the\npostprandial glucose peak 30 min after the oral glucose loading. In\naddition, it is noteworthy that in this study the Zn-based MOF has\nbeen supplied during a short period of time (only 10 days), while\nin the trial conducted by Ohly et al the compound was administered\nfor 4\u20136 weeks. Our results clearly demonstrate that the oral\ntreatment of diabetes with compound 1 improves glucose metabolism,\navoiding the glycemia postprandial rise and achieving basal glycemia\nlevels 120 min after the oral glucose loading.</p>", "clean_text": "The main result obtained in these in vivo experiments is the notable improvement in the oral glucose tolerance test (OGTT) test (). The group of rats treated with the Zn-containing compound developed in this study showed an important decrease of the blood glucose levels 30 min after the oral glucose load in comparison with the untreated diabetic group of rats, which suffered a sustained increase 120 min later. In the Zn treated diabetic group of rats, the glycemia decreased ~18% and ~40%, 30 and 120 min after the oral glucose load, respectively, in comparison with the untreated diabetic rats. Despite the advanced stage of the diabetes, as evidenced by the presence of fasting blood glucose levels higher than 250 mg/dL in the two groups of diabetic rats, compound 1 showed advantages over other conventional compounds tested in other studies at the same dose. The Zn compound tested by Ohly et al. did not achieve a decrease of the postprandial glucose peak 30 min after the oral glucose loading. In addition, it is noteworthy that in this study the Zn-based MOF has been supplied during a short period of time (only 10 days), while in the trial conducted by Ohly et al the compound was administered for 4-6 weeks. Our results clearly demonstrate that the oral treatment of diabetes with compound 1 improves glucose metabolism, avoiding the glycemia postprandial rise and achieving basal glycemia levels 120 min after the oral glucose loading.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 17, "type": "figure", "classification": null, "content": "<fig id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>Oral glucose tolerance\ntest for control, diabetic, and treated diabetic rats after 10 days\nof treatment. Data are presented as mean \u00b1 SD, a, control vs\ndiabetic, b, control vs diabetic treated, and c, diabetic vs diabetic\ntreated. <italic>p</italic> &lt; 0.05.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"cg-2015-012748_0005.tif\"></graphic>\n</fig>", "clean_text": " 4  Oral glucose tolerance test for control, diabetic, and treated diabetic rats after 10 days of treatment. Data are presented as mean \u00b1 SD, a, control vs diabetic, b, control vs diabetic treated, and c, diabetic vs diabetic treated. p < 0.05.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 18, "type": "text", "classification": "error", "content": "<p>In order to confirm compound <bold>1</bold> localization\nwithin the cells, confocal microscopy studies were performed (, <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">S12\u2013S14</ext-link>). Results show that <bold>1</bold> is rapidly\n(2 h) internalized by HEK293 cells and remains in the cytosol at least\nfor 48 h without undergoing chemical degradation or disruption of\nfluorescent properties. These results were corroborated by flow cytometry\nassays (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S14</ext-link>) that revealed a shift\nto higher density values for those cells incubated with <bold>1</bold> in the first 10 min to 48 h compared to control.</p>", "clean_text": "In order to confirm compound 1 localization within the cells, confocal microscopy studies were performed (, S12-S14). Results show that 1 is rapidly (2 h) internalized by HEK293 cells and remains in the cytosol at least for 48 h without undergoing chemical degradation or disruption of fluorescent properties. These results were corroborated by flow cytometry assays (Figure S14) that revealed a shift to higher density values for those cells incubated with 1 in the first 10 min to 48 h compared to control.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>Representative confocal\nimages of live HEK293 in the presence of compound <bold>1</bold>.\nThe images show that compound <bold>1</bold> is distributed on cytosol\nafter 2 h of incubation. Scale bar, 25 \u03bcM. More information\nis in Supporting Information (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figures S12 and S13</ext-link>).</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"cg-2015-012748_0006.tif\"></graphic>\n</fig>", "clean_text": " 5  Representative confocal images of live HEK293 in the presence of compound 1. The images show that compound 1 is distributed on cytosol after 2 h of incubation. Scale bar, 25 \u03bcM. More information is in Supporting Information (Figures S12 and S13).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 20, "type": "text", "classification": "error", "content": "<p>In summary, we have synthesized\na novel zinc MOF based on 5-aminotetrazole and 2-amino-isonicotinic\nanionic ligands and mild hydrothermal routes. The MOF exhibits a 3D\nstructure with intense photoluminescence emission at room temperature\nin the solid state. The synthesized Zn compound in this study exhibited\nan important potential in vivo anti-diabetic activity together with\nlow in vitro cell toxicity. The oral treatment of diabetes with compound <bold>1</bold> improves glucose metabolism, avoiding postprandial glycemia\nrises and achieving basal glycemia levels 120 min after the oral glucose\nloading. To the best of our knowledge, this is the first example of\nan MOF with anti-diabetic capability.</p>", "clean_text": "In summary, we have synthesized a novel zinc MOF based on 5-aminotetrazole and 2-amino-isonicotinic anionic ligands and mild hydrothermal routes. The MOF exhibits a 3D structure with intense photoluminescence emission at room temperature in the solid state. The synthesized Zn compound in this study exhibited an important potential in vivo anti-diabetic activity together with low in vitro cell toxicity. The oral treatment of diabetes with compound 1 improves glucose metabolism, avoiding postprandial glycemia rises and achieving basal glycemia levels 120 min after the oral glucose loading. To the best of our knowledge, this is the first example of an MOF with anti-diabetic capability.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 21, "type": "text", "classification": ["else"], "content": "<p>. The Supporting Information\nis available free of charge on the <ext-link xlink:href=\"http://pubs.acs.org\">ACS Publications website</ext-link> at DOI: <ext-link xlink:href=\"http://pubs.acs.org/doi/abs/10.1021/acs.cgd.5b01274\">10.1021/acs.cgd.5b01274</ext-link>.<list id=\"silist\" list-type=\"label\">\n<list-item>\n<p>Synthesis, crystal\ndata, thermal stability, sorption properties, PSD, luminescence studies,\nSEM image, powder diffraction, cytotoxicity studies, in vivo studies,\nconfocal images and flow cytometry (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">PDF</ext-link>)</p>\n</list-item>\n</list>\n</p>", "clean_text": ". The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.cgd.5b01274.  Synthesis, crystal data, thermal stability, sorption properties, PSD, luminescence studies, SEM image, powder diffraction, cytotoxicity studies, in vivo studies, confocal images and flow cytometry (PDF)   ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 22, "type": "text", "classification": ["else"], "content": "<p>Synthesis, crystal\ndata, thermal stability, sorption properties, PSD, luminescence studies,\nSEM image, powder diffraction, cytotoxicity studies, in vivo studies,\nconfocal images and flow cytometry (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">PDF</ext-link>)</p>", "clean_text": "Synthesis, crystal data, thermal stability, sorption properties, PSD, luminescence studies, SEM image, powder diffraction, cytotoxicity studies, in vivo studies, confocal images and flow cytometry (PDF)", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 23, "type": "text", "classification": ["else"], "content": "<p>CCDC <ext-link ext-link-type=\"ccdc\" xlink:href=\"1403980\">1403980</ext-link> contains the supplementary crystallographic data\nfor this paper. These data can be obtained free of charge via <ext-link xlink:href=\"http://www.ccdc.cam.ac.uk/data_request/cif\">www.ccdc.cam.ac.uk/data_request/cif</ext-link>, or by emailing <email>data_request@ccdc.cam.ac.uk</email>, or by\ncontacting The Cambridge Crystallographic Data Centre, 12, Union Road,\nCambridge CB2 1EZ, UK; fax: +44 1223 336033.</p>", "clean_text": "CCDC 1403980 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 24, "type": "text", "classification": ["property"], "content": "<p>The authors declare no competing\nfinancial interest.</p><title>References</title><p>Crystal Data. <bold>1</bold>: [ZnC<sub>7</sub>H<sub>7</sub>N<sub>7</sub>O<sub>2</sub>], <italic>M</italic> = 286.57, orthorhombic, spacegroup <italic>Pccn</italic>, <italic>a</italic> = 14.5628(46), <italic>b</italic> = 18.7681(62), <italic>c</italic> = 7.7651(26) \u00c5, <italic>V</italic> = 2122.3(16) \u00c5<sup>3</sup>, <italic>Z</italic> = 8, \u03c1<sub>calcd</sub> = 1.794\ng\u00b7cm<sup>\u20133</sup>, \u03bc(Mo-K\u03b1) = 2.317 mm<sup>\u20131</sup>, <italic>R</italic>\n<sub>int</sub> = 0.0822, <italic>T</italic> = 100 K, <italic>R</italic>\n<sub>1</sub>(<italic>F</italic>\n<sub>o</sub>) = 0.0505, (<italic>wR</italic>\n<sub>2</sub>(<italic>F</italic>\n<sub>o</sub>\n<sup>2</sup>) = 0.1061, GOF = 1.007. For more\ninformation, see <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Supporting Information</ext-link>. CCDC: <ext-link ext-link-type=\"ccdc\" xlink:href=\"1403980\">1403980</ext-link>.</p>", "clean_text": "The authors declare no competing financial interest.\n\nReferences\n\nCrystal Data. 1: [ZnC7H7N7O2], M = 286.57, orthorhombic, spacegroup Pccn, a = 14.5628(46), b = 18.7681(62), c = 7.7651(26) \u00c5, V = 2122.3(16) \u00c53, Z = 8, \u03c1calcd = 1.794 g\u22c5cm-3, \u03bc(Mo-K\u03b1) = 2.317 mm-1, R int = 0.0822, T = 100 K, R 1(F o) = 0.0505, (wR 2(F o 2) = 0.1061, GOF = 1.007. For more information, see Supporting Information. CCDC: 1403980.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['property']"}}], "cln_elements": [{"idx": 5, "type": "text", "classification": "synthesis condition", "content": "<p>Soft hydrothermal reaction of zinc acetate\n(0.2 mmol) with 5-aminotetrazole (0.2 mmol) and methyl-2-amino-4-isonicotinic\nacid (0.2 mmol) in water/methanol (10 mL) at 150 \u00b0C for 12 h\nfollowed by cooling to room temperature over 3 h produced prismatic\ncolorless crystals of <bold>1</bold> in 65% yield (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Supporting Information</ext-link>). The crystal structure was determined\nusing single crystal X-ray diffraction. The asymmetric unit consists on one zinc atom, one ain<sup>\u20131</sup> ligand, and one atz<sup>\u20131</sup> linker. Zn ion exhibits\ndistorted tetrahedral ZnN<sub>3</sub>O geometry () with N1B and N4B nitrogen\natoms belonging to tetrazolate group, one oxygen atom pertaining to\na carboxylate group, and a N1A atom from pyridine ring of the anionic\nain<sup>\u20131</sup> ligand.</p>", "clean_text": "Soft hydrothermal reaction of zinc acetate (0.2 mmol) with 5-aminotetrazole (0.2 mmol) and methyl-2-amino-4-isonicotinic acid (0.2 mmol) in water/methanol (10 mL) at 150 \u00b0C for 12 h followed by cooling to room temperature over 3 h produced prismatic colorless crystals of 1 in 65% yield (Supporting Information). The crystal structure was determined using single crystal X-ray diffraction. The asymmetric unit consists on one zinc atom, one ain-1 ligand, and one atz-1 linker. Zn ion exhibits distorted tetrahedral ZnN3O geometry () with N1B and N4B nitrogen atoms belonging to tetrazolate group, one oxygen atom pertaining to a carboxylate group, and a N1A atom from pyridine ring of the anionic ain-1 ligand.", "data": [[{"meta": {"name": "", "symbol": "1", "chemical formula": ""}, "processes": [{"synthesis method": "solvothermal synthesis", "precursor": [{"name": "zinc acetate", "amount": "0.2", "unit": "mmol"}, {"name": "5-aminotetrazole", "amount": "0.2", "unit": "mmol"}, {"name": "methyl-2-amino-4-isonicotinic acid", "amount": "0.2", "unit": "mmol"}], "solvent": [{"name": "water/methanol", "amount": "10", "unit": "mL"}], "reducing agent": [{"name": "", "amount": "", "unit": ""}], "surfactant": [{"name": "", "amount": "", "unit": ""}], "pressure": "", "temperature": "150 \u00b0C", "time": "12 h", "heating rate": "", "cooling rate": "over 3 h"}], "yield": "65%"}]], "include_properties": ["solvothermal_synthesis"], "intermediate_step": {"text-synthesis-type": "['solvothermal_synthesis']", "text-synthesis-struct": "```JSON\n[{\"meta\":{\"name\":\"\", \"symbol\":\"1\", \"chemical formula\":\"\"}, \"processes\":[{\"synthesis method\":\"solvothermal synthesis\", \"precursor\":[{\"name\":\"zinc acetate\", \"amount\":\"0.2\", \"unit\":\"mmol\"}, {\"name\":\"5-aminotetrazole\", \"amount\":\"0.2\", \"unit\":\"mmol\"}, {\"name\":\"methyl-2-amino-4-isonicotinic acid\", \"amount\":\"0.2\", \"unit\":\"mmol\"}], \"solvent\":[{\"name\":\"water/methanol\", \"amount\":\"10\", \"unit\":\"mL\"}], \"reducing agent\":[{\"name\":\"\", \"amount\":\"\", \"unit\":\"\"}], \"surfactant\":[{\"name\":\"\", \"amount\":\"\", \"unit\":\"\"}], \"pressure\":\"\", \"temperature\":\"150 \u00b0C\", \"time\":\"12 h\", \"heating rate\":\"\", \"cooling rate\":\"over 3 h\"}], \"yield\":\"65%\"}]\n```"}}, {"idx": 24, "type": "text", "classification": "property", "content": "<p>The authors declare no competing\nfinancial interest.</p><title>References</title><p>Crystal Data. <bold>1</bold>: [ZnC<sub>7</sub>H<sub>7</sub>N<sub>7</sub>O<sub>2</sub>], <italic>M</italic> = 286.57, orthorhombic, spacegroup <italic>Pccn</italic>, <italic>a</italic> = 14.5628(46), <italic>b</italic> = 18.7681(62), <italic>c</italic> = 7.7651(26) \u00c5, <italic>V</italic> = 2122.3(16) \u00c5<sup>3</sup>, <italic>Z</italic> = 8, \u03c1<sub>calcd</sub> = 1.794\ng\u00b7cm<sup>\u20133</sup>, \u03bc(Mo-K\u03b1) = 2.317 mm<sup>\u20131</sup>, <italic>R</italic>\n<sub>int</sub> = 0.0822, <italic>T</italic> = 100 K, <italic>R</italic>\n<sub>1</sub>(<italic>F</italic>\n<sub>o</sub>) = 0.0505, (<italic>wR</italic>\n<sub>2</sub>(<italic>F</italic>\n<sub>o</sub>\n<sup>2</sup>) = 0.1061, GOF = 1.007. For more\ninformation, see <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Supporting Information</ext-link>. CCDC: <ext-link ext-link-type=\"ccdc\" xlink:href=\"1403980\">1403980</ext-link>.</p>", "clean_text": "The authors declare no competing financial interest.\n\nReferences\n\nCrystal Data. 1: [ZnC7H7N7O2], M = 286.57, orthorhombic, spacegroup Pccn, a = 14.5628(46), b = 18.7681(62), c = 7.7651(26) \u00c5, V = 2122.3(16) \u00c53, Z = 8, \u03c1calcd = 1.794 g\u22c5cm-3, \u03bc(Mo-K\u03b1) = 2.317 mm-1, R int = 0.0822, T = 100 K, R 1(F o) = 0.0505, (wR 2(F o 2) = 0.1061, GOF = 1.007. For more information, see Supporting Information. CCDC: 1403980.", "data": [[[{"meta": {"name": "", "symbol": "1", "chemical formula": "[ZnC7H7N7O2]"}, "chemical formula weight": [{"value": "286.57", "unit": "g/mol", "condition": ""}], "crystal system": [{"value": "orthorhombic", "condition": ""}], "space group": [{"value": "Pccn", "condition": ""}], "lattice parameters": [{"value": {"a": "14.5628", "b": "18.7681", "c": "7.7651", "alpha": "", "beta": "", "gamma": "", "condition": "T = 100 K"}}], "density": [{"value": "1.794", "unit": "g/cm^3", "condition": ""}]}]]], "include_properties": ["chemical_formula_weight", "crystal_system", "space_group", "lattice_parameters", "density"], "intermediate_step": {"categorize": "['property']", "text-property-type": "['chemical_formula_weight', 'crystal_system', 'space_group', 'lattice_parameters', 'density']", "text-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"1\",\n            \"chemical formula\": \"[ZnC7H7N7O2]\"\n        },\n        \"chemical formula weight\": [\n            {\n                \"value\": \"286.57\",\n                \"unit\": \"g/mol\",\n                \"condition\": \"\"\n            }\n        ],\n        \"crystal system\": [\n            {\n                \"value\": \"orthorhombic\",\n                \"condition\": \"\"\n            }\n        ],\n        \"space group\": [\n            {\n                \"value\": \"Pccn\",\n                \"condition\": \"\"\n            }\n        ],\n        \"lattice parameters\": [\n            {\n                \"value\": {\n                    \"a\": \"14.5628\",\n                    \"b\": \"18.7681\",\n                    \"c\": \"7.7651\",\n                    \"alpha\": \"\",\n                    \"beta\": \"\",\n                    \"gamma\": \"\",\n                    \"condition\": \"T = 100 K\"\n                }\n            }\n        ],\n        \"density\": [\n            {\n                \"value\": \"1.794\",\n                \"unit\": \"g/cm^3\",\n                \"condition\": \"\"\n            }\n        ]\n    }\n]\n```"}}, {"idx": 11, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Calculated Emission Bands and Involved Electronic Transitions in\nModel 1</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"3\">\n<oasis:colspec align=\"char\" char=\".\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\">max\u00a0\u03bb (nm) emission</oasis:entry>\n<oasis:entry align=\"center\">calc transitions</oasis:entry>\n<oasis:entry align=\"center\">osc strength</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>376</oasis:entry>\n<oasis:entry>L\u00a0\u2192\u00a0H (88%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>489</oasis:entry>\n<oasis:entry>L+1\u00a0\u2192 H-2 (95%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>513</oasis:entry>\n<oasis:entry>L+1\u00a0\u2192 H-1 (96%)</oasis:entry>\n<oasis:entry>0.0010</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 1. Calculated Emission Bands and Involved Electronic Transitions in Model 1\n\n| max\u00a0\u03bb (nm) emission | calc transitions | osc strength |\n|---------------------|------------------|--------------|\n| 376                 | L\u00a0\u2192\u00a0H (88%)       | 0.0010       |\n| 489                 | L+1\u00a0\u2192 H-2 (95%)   | 0.0010       |\n| 513                 | L+1\u00a0\u2192 H-1 (96%)   | 0.0010       |", "data": {"meta": {"name": "Model 1", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "max \u03bb emission", "value": "376", "unit": "nm", "condition": ""}, {"property name": "calc transitions", "value": "L \u2192 H (88%)", "unit": "", "condition": ""}, {"property name": "osc strength", "value": "0.0010", "unit": "", "condition": ""}, {"property name": "max \u03bb emission", "value": "489", "unit": "nm", "condition": ""}, {"property name": "calc transitions", "value": "L+1 \u2192 H-2 (95%)", "unit": "", "condition": ""}, {"property name": "osc strength", "value": "0.0010", "unit": "", "condition": ""}, {"property name": "max \u03bb emission", "value": "513", "unit": "nm", "condition": ""}, {"property name": "calc transitions", "value": "L+1 \u2192 H-1 (96%)", "unit": "", "condition": ""}, {"property name": "osc strength", "value": "0.0010", "unit": "", "condition": ""}]}, "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 1. Calculated Emission Bands and Involved Electronic Transitions in Model 1\n\n| max\u00a0\u03bb (nm) emission | calc transitions | osc strength |\n|---------------------|------------------|--------------|\n| 376                 | L\u00a0\u2192\u00a0H (88%)       | 0.0010       |\n| 489                 | L+1\u00a0\u2192 H-2 (95%)   | 0.0010       |\n| 513                 | L+1\u00a0\u2192 H-1 (96%)   | 0.0010       |\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n{\n    \"meta\": {\n        \"name\": \"Model 1\",\n        \"symbol\": \"\",\n        \"chemical formula\": \"\",\n    },\n    \"etc\": [\n        {\n            \"property name\": \"max \u03bb emission\",\n            \"value\": \"376\",\n            \"unit\": \"nm\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"calc transitions\",\n            \"value\": \"L \u2192 H (88%)\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"osc strength\",\n            \"value\": \"0.0010\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"max \u03bb emission\",\n            \"value\": \"489\",\n            \"unit\": \"nm\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"calc transitions\",\n            \"value\": \"L+1 \u2192 H-2 (95%)\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"osc strength\",\n            \"value\": \"0.0010\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"max \u03bb emission\",\n            \"value\": \"513\",\n            \"unit\": \"nm\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"calc transitions\",\n            \"value\": \"L+1 \u2192 H-1 (96%)\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        },\n        {\n            \"property name\": \"osc strength\",\n            \"value\": \"0.0010\",\n            \"unit\": \"\",\n            \"condition\": \"\",\n        }\n    ]\n}\n```"}}, {"idx": 15, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl2\" position=\"float\">\n<label>2</label>\n<caption>\n<title>Data Are Presented\nAs Mean \u00b1 SD<xref rid=\"tbl2-fn1\"></xref>\n</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"5\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\"\u00b1\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\"\u00b1\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"center\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"center\" colname=\"col5\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">body weight (g)</oasis:entry>\n<oasis:entry align=\"center\">food intake (g)</oasis:entry>\n<oasis:entry align=\"center\">water\nintake (mL)</oasis:entry>\n<oasis:entry align=\"center\">fasting glycemia (mg/dL)</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>control</oasis:entry>\n<oasis:entry>256\u00a0\u00b1\u00a07</oasis:entry>\n<oasis:entry>16.5\u00a0\u00b1\u00a00.7</oasis:entry>\n<oasis:entry>15.3\u00a0\u00b1\u00a06.1</oasis:entry>\n<oasis:entry>81.3\u00a0\u00b1\u00a05.4</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>diabetic</oasis:entry>\n<oasis:entry>223\u00a0\u00b1\u00a017<sup>a</sup>\n</oasis:entry>\n<oasis:entry>42.3\u00a0\u00b1\u00a00.9<sup>a</sup>\n</oasis:entry>\n<oasis:entry>310.2\u00a0\u00b1\u00a028.7<sup>a</sup>\n</oasis:entry>\n<oasis:entry>272.8\u00a0\u00b1\u00a018<sup>a</sup>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>diabetic treated</oasis:entry>\n<oasis:entry>217\u00a0\u00b1\u00a012<sup>b</sup>\n</oasis:entry>\n<oasis:entry>35.7\u00a0\u00b1\u00a00.5<sup>b,c</sup>\n</oasis:entry>\n<oasis:entry>190.1\u00a0\u00b1\u00a042.8<sup>b,c</sup>\n</oasis:entry>\n<oasis:entry>237.3\u00a0\u00b1\u00a022<sup>b,c</sup>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"tbl2-fn1\">\n<label>a</label>\n<p>a, control vs diabetic, b, control vs diabetic treated, and c, diabetic\nvs diabetic treated. <italic>p</italic> &lt; 0.05.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 2. Data Are Presented As Mean \u00b1 SD[^a]\n\n|          | body weight (g) | food intake (g) | water intake (mL) | fasting glycemia (mg/dL) |\n|----------|-----------------|------------------|-------------------|--------------------------|\n| control  | 256 \u00b1 7         | 16.5 \u00b1 0.7       | 15.3 \u00b1 6.1        | 81.3 \u00b1 5.4               |\n| diabetic | 223 \u00b1 17[^a]    | 42.3 \u00b1 0.9[^a]   | 310.2 \u00b1 28.7[^a]  | 272.8 \u00b1 18[^a]            |\n| diabetic treated | 217 \u00b1 12[^b] | 35.7 \u00b1 0.5[^b,c] | 190.1 \u00b1 42.8[^b,c] | 237.3 \u00b1 22[^b,c]          |\n\n[^a]: a, control vs diabetic, b, control vs diabetic treated, and c, diabetic vs diabetic treated. p < 0.05.", "data": [[{"meta": {"name": "control", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "body weight", "value": "256 \u00b1 7", "unit": "g", "condition": ""}, {"property name": "food intake", "value": "16.5 \u00b1 0.7", "unit": "g", "condition": ""}, {"property name": "water intake", "value": "15.3 \u00b1 6.1", "unit": "mL", "condition": ""}, {"property name": "fasting glycemia", "value": "81.3 \u00b1 5.4", "unit": "mg/dL", "condition": ""}]}, {"meta": {"name": "diabetic", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "body weight", "value": "223 \u00b1 17", "unit": "g", "condition": "a"}, {"property name": "food intake", "value": "42.3 \u00b1 0.9", "unit": "g", "condition": "a"}, {"property name": "water intake", "value": "310.2 \u00b1 28.7", "unit": "mL", "condition": "a"}, {"property name": "fasting glycemia", "value": "272.8 \u00b1 18", "unit": "mg/dL", "condition": "a"}]}, {"meta": {"name": "diabetic treated", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "body weight", "value": "217 \u00b1 12", "unit": "g", "condition": "b"}, {"property name": "food intake", "value": "35.7 \u00b1 0.5", "unit": "g", "condition": "b,c"}, {"property name": "water intake", "value": "190.1 \u00b1 42.8", "unit": "mL", "condition": "b,c"}, {"property name": "fasting glycemia", "value": "237.3 \u00b1 22", "unit": "mg/dL", "condition": "b,c"}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 2. Data Are Presented As Mean \u00b1 SD[^a]\n\n|          | body weight (g) | food intake (g) | water intake (mL) | fasting glycemia (mg/dL) |\n|----------|-----------------|------------------|-------------------|--------------------------|\n| control  | 256 \u00b1 7         | 16.5 \u00b1 0.7       | 15.3 \u00b1 6.1        | 81.3 \u00b1 5.4               |\n| diabetic | 223 \u00b1 17[^a]    | 42.3 \u00b1 0.9[^a]   | 310.2 \u00b1 28.7[^a]  | 272.8 \u00b1 18[^a]            |\n| diabetic treated | 217 \u00b1 12[^b] | 35.7 \u00b1 0.5[^b,c] | 190.1 \u00b1 42.8[^b,c] | 237.3 \u00b1 22[^b,c]          |\n\n[^a]: a, control vs diabetic, b, control vs diabetic treated, and c, diabetic vs diabetic treated. p < 0.05.\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"control\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"body weight\",\n                \"value\": \"256 \u00b1 7\",\n                \"unit\": \"g\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"food intake\",\n                \"value\": \"16.5 \u00b1 0.7\",\n                \"unit\": \"g\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"water intake\",\n                \"value\": \"15.3 \u00b1 6.1\",\n                \"unit\": \"mL\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"fasting glycemia\",\n                \"value\": \"81.3 \u00b1 5.4\",\n                \"unit\": \"mg/dL\",\n                \"condition\": \"\",\n            }\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"diabetic\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"body weight\",\n                \"value\": \"223 \u00b1 17\",\n                \"unit\": \"g\",\n                \"condition\": \"a\",\n            },\n            {\n                \"property name\": \"food intake\",\n                \"value\": \"42.3 \u00b1 0.9\",\n                \"unit\": \"g\",\n                \"condition\": \"a\",\n            },\n            {\n                \"property name\": \"water intake\",\n                \"value\": \"310.2 \u00b1 28.7\",\n                \"unit\": \"mL\",\n                \"condition\": \"a\",\n            },\n            {\n                \"property name\": \"fasting glycemia\",\n                \"value\": \"272.8 \u00b1 18\",\n                \"unit\": \"mg/dL\",\n                \"condition\": \"a\",\n            }\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"diabetic treated\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"body weight\",\n                \"value\": \"217 \u00b1 12\",\n                \"unit\": \"g\",\n                \"condition\": \"b\",\n            },\n            {\n                \"property name\": \"food intake\",\n                \"value\": \"35.7 \u00b1 0.5\",\n                \"unit\": \"g\",\n                \"condition\": \"b,c\",\n            },\n            {\n                \"property name\": \"water intake\",\n                \"value\": \"190.1 \u00b1 42.8\",\n                \"unit\": \"mL\",\n                \"condition\": \"b,c\",\n            },\n            {\n                \"property name\": \"fasting glycemia\",\n                \"value\": \"237.3 \u00b1 22\",\n                \"unit\": \"mg/dL\",\n                \"condition\": \"b,c\",\n            }\n        ],\n    }\n]\n```"}}, {"idx": 6, "type": "figure", "classification": null, "content": "<fig id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>A view of the metal environment and coordination\nmodes of the ligands for 1. Color code: N = blue, O = red, C = gray,\nZn = yellow.</p>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"cg-2015-012748_0002.tif\"></graphic>\n</fig>", "clean_text": " 1  A view of the metal environment and coordination modes of the ligands for 1. Color code: N = blue, O = red, C = gray, Zn = yellow.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 8, "type": "figure", "classification": null, "content": "<fig id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>View down the <italic>b</italic> axis of the structure in the three-dimensional network.\nHydrogen atoms have been omitted for clarity. Color code: N = blue,\nO = red, C = gray, Zn = yellow.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"cg-2015-012748_0003.tif\"></graphic>\n</fig>", "clean_text": " 2  View down the b axis of the structure in the three-dimensional network. Hydrogen atoms have been omitted for clarity. Color code: N = blue, O = red, C = gray, Zn = yellow.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Calculated normalized\nemission spectrum of model 1, upon application of a Gaussian filter\nto theoretical data (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figure S8</ext-link>). The three\nmaxima observed in the original spectrum are indicated as red circles.</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"cg-2015-012748_0004.tif\"></graphic>\n</fig>", "clean_text": " 3  Calculated normalized emission spectrum of model 1, upon application of a Gaussian filter to theoretical data (Figure S8). The three maxima observed in the original spectrum are indicated as red circles.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 17, "type": "figure", "classification": null, "content": "<fig id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>Oral glucose tolerance\ntest for control, diabetic, and treated diabetic rats after 10 days\nof treatment. Data are presented as mean \u00b1 SD, a, control vs\ndiabetic, b, control vs diabetic treated, and c, diabetic vs diabetic\ntreated. <italic>p</italic> &lt; 0.05.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"cg-2015-012748_0005.tif\"></graphic>\n</fig>", "clean_text": " 4  Oral glucose tolerance test for control, diabetic, and treated diabetic rats after 10 days of treatment. Data are presented as mean \u00b1 SD, a, control vs diabetic, b, control vs diabetic treated, and c, diabetic vs diabetic treated. p < 0.05.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>Representative confocal\nimages of live HEK293 in the presence of compound <bold>1</bold>.\nThe images show that compound <bold>1</bold> is distributed on cytosol\nafter 2 h of incubation. Scale bar, 25 \u03bcM. More information\nis in Supporting Information (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.5b01274/suppl_file/cg5b01274_si_001.pdf\">Figures S12 and S13</ext-link>).</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"cg-2015-012748_0006.tif\"></graphic>\n</fig>", "clean_text": " 5  Representative confocal images of live HEK293 in the presence of compound 1. The images show that compound 1 is distributed on cytosol after 2 h of incubation. Scale bar, 25 \u03bcM. More information is in Supporting Information (Figures S12 and S13).   ", "data": null, "include_properties": null, "intermediate_step": {}}], "metadata": {"doi": "10.1021/acs.cgd.5b01274", "title": "\nHighly Active Anti-Diabetic Metal\u2013Organic Framework\n", "journal": "American Chemical\nSociety", "date": "2015.12", "author_list": ["Briones\nDavid", "Ferna\u0301ndez\nBele\u0301n", "Calahorro\nAntonio\nJ.", "Fairen-Jimenez\nDavid", "Sanz\nRau\u0301l", "Marti\u0301nez\nFernando", "Orcajo\nGisela", "Sebastia\u0301n\nEider San", "Seco\nJose\u0301 M.", "Gonza\u0301lez\nCristina Sa\u0301nchez", "Llopis\nJuan", "Rodri\u0301guez-Die\u0301guez\nAntonio"]}}